Download PDF
Digestive Disease Interventions 2017; 01(03): 225-232
DOI: 10.1055/s-0037-1607964
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Future Interventional Oncology Catheter-Based Therapies

Christopher Hiro Noda
1   Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
,
Mihail Roubhaka
1   Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
,
Resmi Charalel
1   Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
,
Abdulrahman Masrani
1   Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
,
Olaguoke Akinwande
1   Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
› Author Affiliations
Further Information

Publication History

26 August 2017

21 September 2017

Publication Date:
09 November 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Minimally invasive techniques in the treatment of cancer continue to develop at a rapid pace. Although surgical resection currently remains the only option for a complete cure, not all diseases are amenable to complete removal. This leaves opportunities to develop effective downstaging techniques as well as palliative care. In the realm of minimally invasive oncologic techniques, catheter-based therapies are an attractive option because malignancies require a blood supply to remain active. The intra-arterial (IA) delivery of specific tumoricidal drugs has been shown to be a successful delivery method in a variety of different cancers, and it is currently a progressive area of research. There is work both to increase the delivery specificity of oncologic drugs, including SW43 sigma receptor ligand and nanoparticle research. In addition, oncolytic viral therapy and 3-bromopyruvate have become increasingly more attractive tumoricidal drug prospects. In the future, the success of these therapies will ultimately determine the degree to which IA delivery will compete with the systemic delivery of drugs in the treatment of cancer.

Keywords

oncology - interventional - catheter-based techniques - minimally invasive
 

  • References

  • 1 Hoffer FA. Interventional oncology: the future. Pediatr Radiol 2011; 41 (Suppl. 01) S201-S206
    CrossrefPubMedGoogle Scholar
  • 2 Mackie CR, Noble HG, Cooper MJ, Collins P, Block GE, Moossa AR. Prospective evaluation of angiography in the diagnosis and management of patients suspected of having pancreatic cancer. Ann Surg 1979; 189 (01) 11-17
    CrossrefPubMedGoogle Scholar
  • 3 Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971; 28 (05) 1165-1177
    CrossrefPubMedGoogle Scholar
  • 4 Weyman PJ, McClennan BL, Stanley RJ, Levitt RG, Sagel SS. Comparison of computed tomography and angiography in the evaluation of renal cell carcinoma. Radiology 1980; 137 (02) 417-424
    CrossrefPubMedGoogle Scholar
  • 5 Reuter SR, Redman HC, Siders DB. The spectrum of angiographic findings in hepatoma. Radiology 1970; 94 (01) 89-94
    CrossrefPubMedGoogle Scholar
  • 6 Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol 2015; 88 (1052): 20140564
    CrossrefPubMedGoogle Scholar
  • 7 Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30 (05) 969-977
    PubMedGoogle Scholar
  • 8 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37 (02) 429-442
    CrossrefPubMedGoogle Scholar
  • 9 Salem R, Lewandowski RJ, Kulik L. , et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140 (02) 497-507.e2
    CrossrefPubMedGoogle Scholar
  • 10 Salem R, Lewandowski RJ, Mulcahy MF. , et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
    CrossrefPubMedGoogle Scholar
  • 11 Doolittle ND, Miner ME, Hall WA. , et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000; 88 (03) 637-647
    CrossrefPubMedGoogle Scholar
  • 12 Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008; 115 (08) 1398-1404 , 1404.e1
    CrossrefPubMedGoogle Scholar
  • 13 Kato T, Nemoto R, Mori H, Takahashi M, Harada M. Arterial chemoembolization with mitomycin C microcapsules in the treatment of primary or secondary carcinoma of the kidney, liver, bone and intrapelvic organs. Cancer 1981; 48 (03) 674-680
    CrossrefPubMedGoogle Scholar
  • 14 Sheth RA, Hesketh R, Kong DS, Wicky S, Oklu R. Barriers to drug delivery in interventional oncology. J Vasc Interv Radiol 2013; 24 (08) 1201-1207
    CrossrefPubMedGoogle Scholar
  • 15 Aydar E, Palmer CP, Djamgoz MB. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res 2004; 64 (15) 5029-5035
    CrossrefPubMedGoogle Scholar
  • 16 Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995; 55 (02) 408-413
    PubMedGoogle Scholar
  • 17 Bem WT, Thomas GE, Mamone JY. , et al. Overexpression of sigma receptors in nonneural human tumors. Cancer Res 1991; 51 (24) 6558-6562
    PubMedGoogle Scholar
  • 18 Xu J, Zeng C, Chu W. , et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011; 2: 380
    CrossrefPubMedGoogle Scholar
  • 19 Ludwig JM, Gai Y, Sun L, Xiang G, Zeng D, Kim HS. SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - an in vitro evaluation. Mol Oncol 2016; 10 (07) 1133-1145
    CrossrefPubMedGoogle Scholar
  • 20 Hashim YM, Spitzer D, Vangveravong S. , et al. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Mol Oncol 2014; 8 (05) 956-967
    CrossrefPubMedGoogle Scholar
  • 21 Ludwig JM, Xing M, Gai Y, Sun L, Zeng D, Kim HS. Targeted yttrium 89-doxorubicin drug-eluting bead-a safety and feasibility pilot study in a rabbit liver cancer model. Mol Pharm 2017; 14 (08) 2824-2830
    CrossrefPubMedGoogle Scholar
  • 22 Warburg O. On the origin of cancer cells. Science 1956; 123 (3191): 309-314
    CrossrefPubMedGoogle Scholar
  • 23 Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R. , et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res 2009; 29 (12) 4909-4918
    PubMedGoogle Scholar
  • 24 Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25 (34) 4633-4646
    CrossrefPubMedGoogle Scholar
  • 25 Ganapathy-Kanniappan S, Kunjithapatham R, Torbenson MS. , et al. Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology 2012; 262 (03) 834-845
    CrossrefPubMedGoogle Scholar
  • 26 Yadav S, Pandey SK, Kumar A, Kujur PK, Singh RP, Singh SM. Antitumor and chemosensitizing action of 3-bromopyruvate: implication of deregulated metabolism. Chem Biol Interact 2017; 270: 73-89
    CrossrefPubMedGoogle Scholar
  • 27 Chapiro J, Sur S, Savic LJ. , et al. Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. Clin Cancer Res 2014; 20 (24) 6406-6417
    CrossrefPubMedGoogle Scholar
  • 28 Choi YH, Chung JW, Son KR. , et al. Novel intraarterial therapy for liver cancer using ethylbromopyruvate dissolved in an iodized oil. Acad Radiol 2011; 18 (04) 471-478
    CrossrefPubMedGoogle Scholar
  • 29 Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002; 62 (14) 3909-3913
    PubMedGoogle Scholar
  • 30 Liapi E, Geschwind JF, Vali M. , et al. Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor. J Nucl Med 2011; 52 (02) 225-230
    CrossrefPubMedGoogle Scholar
  • 31 Vali M, Vossen JA, Buijs M. , et al. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther 2008; 327 (01) 32-37
    CrossrefPubMedGoogle Scholar
  • 32 Kunjithapatham R, Geschwind JF, Rao PP, Boronina TN, Cole RN, Ganapathy-Kanniappan S. Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model. BMC Res Notes 2013; 6: 277
    CrossrefPubMedGoogle Scholar
  • 33 Phillips WT, Bao A, Brenner AJ, Goins BA. Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles. Adv Drug Deliv Rev 2014; 76: 39-59
    CrossrefPubMedGoogle Scholar
  • 34 Sanvicens N, Marco MP. Multifunctional nanoparticles--properties and prospects for their use in human medicine. Trends Biotechnol 2008; 26 (08) 425-433
    CrossrefPubMedGoogle Scholar
  • 35 Liu Y, Welch MJ. Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. Bioconjug Chem 2012; 23 (04) 671-682
    CrossrefPubMedGoogle Scholar
  • 36 Liu Y, Zhang N. Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging. Biomaterials 2012; 33 (21) 5363-5375
    CrossrefPubMedGoogle Scholar
  • 37 Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011; 63 (03) 131-135
    CrossrefPubMedGoogle Scholar
  • 38 Wen X, Reynolds L, Mulik RS. , et al. Hepatic arterial infusion of low-density lipoprotein docosahexaenoic acid nanoparticles selectively disrupts redox balance in hepatoma cells and reduces growth of orthotopic liver tumors in tats. Gastroenterology 2016; 150 (02) 488-498
    CrossrefPubMedGoogle Scholar
  • 39 Lencioni R, Braet F. Novel transarterial biomimetic-based nanoparticles for the treatment of hepatocellular carcinoma. Gastroenterology 2016; 150 (02) 312-314
    CrossrefPubMedGoogle Scholar
  • 40 Reynolds L, Mulik RS, Wen X, Dilip A, Corbin IR. Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells. Nanomedicine (Lond) 2014; 9 (14) 2123-2141
    CrossrefPubMedGoogle Scholar
  • 41 Black KC, Wang Y, Luehmann HP. , et al. Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. ACS Nano 2014; 8 (05) 4385-4394
    CrossrefPubMedGoogle Scholar
  • 42 Ellis JA, Banu M, Hossain SS. , et al. Reassessing the role of intra-arterial drug delivery for glioblastoma multiforme treatment. J Drug Deliv 2015; 2015: 405735
    PubMedGoogle Scholar
  • 43 Gupta S, Stafford RJ, Javadi S. , et al. Effects of near-infrared laser irradiation of biodegradable microspheres containing hollow gold nanospheres and paclitaxel administered intraarterially in a rabbit liver tumor model. J Vasc Interv Radiol 2012; 23 (04) 553-561
    CrossrefPubMedGoogle Scholar
  • 44 Stephens RW, Knox KJ, Philip LA. , et al. The uptake of soluble and nanoparticulate imaging isotope in model liver tumours after intra-venous and intra-arterial administration. Biomaterials 2015; 39: 218-224
    CrossrefPubMedGoogle Scholar
  • 45 Damascelli B, Cantù G, Mattavelli F. , et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 2001; 92 (10) 2592-2602
    CrossrefPubMedGoogle Scholar
  • 46 Nishiofuku H, Tanaka T, Fukuoka Y. , et al. Intraarterial therapy using micellar nanoparticles incorporating SN-38 in a rabbit liver tumor model. J Vasc Interv Radiol 2017; 28 (03) 457-464
    CrossrefPubMedGoogle Scholar
  • 47 Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther 2016; 33 (05) 699-714
    CrossrefPubMedGoogle Scholar
  • 48 You J, Zhao J, Wen X. , et al. Chemoradiation therapy using cyclopamine-loaded liquid-lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles. J Control Release 2015; 202: 40-48
    CrossrefPubMedGoogle Scholar
  • 49 Li S, Wang M, Liu B. , et al. Lutetium-methanediide-alkyl complexes: synthesis and chemistry. Chemistry 2014; 20 (47) 15493-15498
    CrossrefPubMedGoogle Scholar
  • 50 Bouchat V, Nuttens VE, Michiels C. , et al. Radioimmunotherapy with radioactive nanoparticles: biological doses and treatment efficiency for vascularized tumors with or without a central hypoxic area. Med Phys 2010; 37 (04) 1826-1839
    CrossrefPubMedGoogle Scholar
  • 51 Bozkurt MF, Salanci BV, Uğur Ö. Intra-arterial radionuclide therapies for liver tumors. Semin Nucl Med 2016; 46 (04) 324-339
    CrossrefPubMedGoogle Scholar
  • 52 Di Pasqua AJ, Huckle JE, Kim JK. , et al. Preparation of neutron-activatable holmium nanoparticles for the treatment of ovarian cancer metastases. Small 2012; 8 (07) 997-1000
    CrossrefPubMedGoogle Scholar
  • 53 Sohn JH, Choi HJ, Lee JT. , et al. Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. Oncology 2009; 76 (01) 1-9
    CrossrefPubMedGoogle Scholar
  • 54 Smits ML, van den Bosch MA, Nijsen JF, Zonnenberg BA. The evolution of radioembolisation. Lancet Oncol 2012; 13 (12) e519
    CrossrefPubMedGoogle Scholar
  • 55 Fiandaca MS, Berger MS, Bankiewicz KS. The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel) 2011; 3 (04) 369-397
    CrossrefPubMedGoogle Scholar
  • 56 Phillips WT, Goins B, Bao A. , et al. Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma. Neuro-oncol 2012; 14 (04) 416-425
    PubMedGoogle Scholar
  • 57 Sze DY, Reid TR, Rose SC. Oncolytic virotherapy. J Vasc Interv Radiol 2013; 24 (08) 1115-1122
    CrossrefPubMedGoogle Scholar
  • 58 Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci 2016; 107 (10) 1373-1379
    CrossrefPubMedGoogle Scholar
  • 59 Bell J, McFadden G. Viruses for tumor therapy. Cell Host Microbe 2014; 15 (03) 260-265
    CrossrefPubMedGoogle Scholar
  • 60 Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011; 19 (06) 1008-1016
    CrossrefPubMedGoogle Scholar
  • 61 Boisgerault N, Achard C, Delaunay T. , et al. Oncolytic virotherapy for human malignant mesothelioma: recent advances. Oncolytic Virother 2015; 4: 133-140
    PubMedGoogle Scholar
  • 62 Jebar AH, Errington-Mais F, Vile RG, Selby PJ, Melcher AA, Griffin S. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. J Gen Virol 2015; 96 (Pt 7): 1533-1550
    CrossrefPubMedGoogle Scholar
  • 63 Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 2014; 22 (05) 1056-1062
    CrossrefPubMedGoogle Scholar
  • 64 Lin XJ, Li QJ, Lao XM, Yang H, Li SP. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). BMC Cancer 2015; 15: 707
    CrossrefPubMedGoogle Scholar
  • 65 Andtbacka RH, Kaufman HL, Collichio F. , et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33 (25) 2780-2788
    CrossrefPubMedGoogle Scholar
  • 66 Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14 (09) 642-662
    CrossrefPubMedGoogle Scholar
  • 67 Strobl H, Knapp W. TGF-beta1 regulation of dendritic cells. Microbes Infect 1999; 1 (15) 1283-1290
    CrossrefPubMedGoogle Scholar
  • 68 Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010; 18 (02) 251-263
    CrossrefPubMedGoogle Scholar
  • 69 Prestwich RJ, Errington F, Steele LP. , et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 2009; 183 (07) 4312-4321
    CrossrefPubMedGoogle Scholar